MARKET

ESLA

ESLA

Estrella Immunopharma
NASDAQ
1.390
-0.170
-10.90%
After Hours: 1.440 +0.05 +3.60% 19:22 01/02 EST
OPEN
1.520
PREV CLOSE
1.560
HIGH
1.520
LOW
1.380
VOLUME
20.84K
TURNOVER
--
52 WEEK HIGH
3.150
52 WEEK LOW
0.7301
MARKET CAP
52.49M
P/E (TTM)
-3.7608
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESLA last week (1222-1226)?
Weekly Report · 12/29/2025 10:07
Estrella Immunopharma Offers Up To 2,541,206 Shares For Resale By The Selling Stockholders
Benzinga · 12/22/2025 16:00
ESTRELLA IMMUNOPHARMA INC - OFFERS UP TO 2,541,206 SHARES FOR RESALE BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 12/22/2025 15:57
Weekly Report: what happened at ESLA last week (1215-1219)?
Weekly Report · 12/22/2025 10:07
Weekly Report: what happened at ESLA last week (1208-1212)?
Weekly Report · 12/15/2025 10:13
Weekly Report: what happened at ESLA last week (1201-1205)?
Weekly Report · 12/08/2025 10:11
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II
TipRanks · 12/04/2025 14:47
Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review
TipRanks · 12/04/2025 13:15
More
About ESLA
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

Webull offers Estrella Immunopharma Inc stock information, including NASDAQ: ESLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESLA stock methods without spending real money on the virtual paper trading platform.